Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20386958 | 0.95 | CNR2 (0.36) | CNR2RORCCYP11B1CYP11B2MCHR1 | |
| SCHEMBL20386813 | 0.92 | CNR2 (0.34) | CNR2RORCCYP11B1CYP11B2MCHR1 | |
| SCHEMBL20386808 | 0.91 | CNR2 (0.35) | CNR2RORCMCHR1KCNH2 | |
| SCHEMBL20386807 | 0.90 | CNR2 (0.32) | CNR2RORCCYP11B1CYP11B2MCHR1 | |
| SCHEMBL20386962 | 0.88 | CNR2 (0.38) | CNR2RORCCYP11B1CYP11B2KCNH2 | |
| SCHEMBL20386960 | 0.86 | CNR2 (0.33) | CNR2RORCCYP11B1CYP11B2MCHR1 | |
| SCHEMBL19876674 | 0.84 | NR1H2 (0.32) | CNR2RORCCYP11B1CYP11B2MCHR1 | |
| SCHEMBL19888424 | 0.84 | NR1H2 (0.32) | CNR2RORCCYP11B1CYP11B2 | |
| SCHEMBL29683582 | 0.84 | NR1H2 (0.32) | CNR2RORCCYP11B1CYP11B2MCHR1 | |
| SCHEMBL20386941 | 0.83 | TLR7 (0.36) | CNR2TLR7ALOX5APMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110382485-B | Heterocyclene derivatives as pest control agents | 拜耳公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11058115-B2 | Heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-13 | — | — | US | disclosed |
| US-11058115-B2 | Heterocycle derivatives as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-07-13 | — | — | US | disclosed |
| EP-3568392-B1 | IMIDAZOLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3568392-B1 | IMIDAZOLE DERIVATIVES AS PEST CONTROL AGENTS | BAYER AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-20200054017-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200054017-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2020-02-20 | — | — | US | disclosed |
| WO-2018130437-A1 | HETEROCYCLENE DERIVATIVES AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058115-B2 | Heterocycle derivatives as pesticides | DDT, CBR3, CBR1 | CNR2 624/4885TLR7 3336/4885TLR8 4678/4885 |
| US-20200054017-A1 | HETEROCYCLE DERIVATIVES AS PESTICIDES | DDT, CBR3, CBR1 | CNR2 624/4885TLR7 3336/4885TLR8 4678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.